Coronary Edema Demonstrated by Cardiovascular Magnetic Resonance in Patients with Peri-Stent Inflammation and Aneurysm Formation after Treatment by Drug-Eluting Stents
Niels R. Holm,Won Yong Kim,Michael Maeng,Samuel A. Thrysoe,Hans Erik Botker,Leif Thuesen,Soren Hoyer,Shengxian Tu,Erling Falk,Jens Flensted Lassen,Per Hostrup Nielsen,Evald Hoj Christiansen
DOI: https://doi.org/10.1161/circimaging.112.979997
2013-01-01
Abstract:HomeCirculation: Cardiovascular ImagingVol. 6, No. 2Coronary Edema Demonstrated by Cardiovascular Magnetic Resonance in Patients With Peri-Stent Inflammation and Aneurysm Formation After Treatment by Drug-Eluting Stents Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissionsDownload Articles + Supplements ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toSupplemental MaterialFree AccessResearch ArticlePDF/EPUBCoronary Edema Demonstrated by Cardiovascular Magnetic Resonance in Patients With Peri-Stent Inflammation and Aneurysm Formation After Treatment by Drug-Eluting Stents Niels R. Holm, MD, Won Yong Kim, MD, PhD, Michael Maeng, MD, PhD, Samuel A. Thrysøe, PhD, Hans Erik Bøtker, MD, DMSc, Leif Thuesen, MD, DMSc, Søren Høyer, MD, Shengxian Tu, PhD, Erling Falk, MD, DMSc, Jens Flensted Lassen, MD, PhD, Per Hostrup Nielsen, MD and Evald Høj Christiansen, MD, PhD Niels R. HolmNiels R. Holm From the Department of Cardiology (N.R.H., W.Y.K., M.M., H.E.B., L.T., E.F., J.F.L., E.H.C.), MR-Center (W.Y.K., S.A.T.), and Department of Pathology (S.H.), Aarhus University Hospital, Skejby, Denmark; Division of Image Processing, Leiden University Medical Center, Leiden, the Netherlands (S.T.); and Department of Thoracic Surgery, Aarhus University Hospital, Skejby, Aarhus, Denmark (P.H.N.). Search for more papers by this author , Won Yong KimWon Yong Kim From the Department of Cardiology (N.R.H., W.Y.K., M.M., H.E.B., L.T., E.F., J.F.L., E.H.C.), MR-Center (W.Y.K., S.A.T.), and Department of Pathology (S.H.), Aarhus University Hospital, Skejby, Denmark; Division of Image Processing, Leiden University Medical Center, Leiden, the Netherlands (S.T.); and Department of Thoracic Surgery, Aarhus University Hospital, Skejby, Aarhus, Denmark (P.H.N.). Search for more papers by this author , Michael MaengMichael Maeng From the Department of Cardiology (N.R.H., W.Y.K., M.M., H.E.B., L.T., E.F., J.F.L., E.H.C.), MR-Center (W.Y.K., S.A.T.), and Department of Pathology (S.H.), Aarhus University Hospital, Skejby, Denmark; Division of Image Processing, Leiden University Medical Center, Leiden, the Netherlands (S.T.); and Department of Thoracic Surgery, Aarhus University Hospital, Skejby, Aarhus, Denmark (P.H.N.). Search for more papers by this author , Samuel A. ThrysøeSamuel A. Thrysøe From the Department of Cardiology (N.R.H., W.Y.K., M.M., H.E.B., L.T., E.F., J.F.L., E.H.C.), MR-Center (W.Y.K., S.A.T.), and Department of Pathology (S.H.), Aarhus University Hospital, Skejby, Denmark; Division of Image Processing, Leiden University Medical Center, Leiden, the Netherlands (S.T.); and Department of Thoracic Surgery, Aarhus University Hospital, Skejby, Aarhus, Denmark (P.H.N.). Search for more papers by this author , Hans Erik BøtkerHans Erik Bøtker From the Department of Cardiology (N.R.H., W.Y.K., M.M., H.E.B., L.T., E.F., J.F.L., E.H.C.), MR-Center (W.Y.K., S.A.T.), and Department of Pathology (S.H.), Aarhus University Hospital, Skejby, Denmark; Division of Image Processing, Leiden University Medical Center, Leiden, the Netherlands (S.T.); and Department of Thoracic Surgery, Aarhus University Hospital, Skejby, Aarhus, Denmark (P.H.N.). Search for more papers by this author , Leif ThuesenLeif Thuesen From the Department of Cardiology (N.R.H., W.Y.K., M.M., H.E.B., L.T., E.F., J.F.L., E.H.C.), MR-Center (W.Y.K., S.A.T.), and Department of Pathology (S.H.), Aarhus University Hospital, Skejby, Denmark; Division of Image Processing, Leiden University Medical Center, Leiden, the Netherlands (S.T.); and Department of Thoracic Surgery, Aarhus University Hospital, Skejby, Aarhus, Denmark (P.H.N.). Search for more papers by this author , Søren HøyerSøren Høyer From the Department of Cardiology (N.R.H., W.Y.K., M.M., H.E.B., L.T., E.F., J.F.L., E.H.C.), MR-Center (W.Y.K., S.A.T.), and Department of Pathology (S.H.), Aarhus University Hospital, Skejby, Denmark; Division of Image Processing, Leiden University Medical Center, Leiden, the Netherlands (S.T.); and Department of Thoracic Surgery, Aarhus University Hospital, Skejby, Aarhus, Denmark (P.H.N.). Search for more papers by this author , Shengxian TuShengxian Tu From the Department of Cardiology (N.R.H., W.Y.K., M.M., H.E.B., L.T., E.F., J.F.L., E.H.C.), MR-Center (W.Y.K., S.A.T.), and Department of Pathology (S.H.), Aarhus University Hospital, Skejby, Denmark; Division of Image Processing, Leiden University Medical Center, Leiden, the Netherlands (S.T.); and Department of Thoracic Surgery, Aarhus University Hospital, Skejby, Aarhus, Denmark (P.H.N.). Search for more papers by this author , Erling FalkErling Falk From the Department of Cardiology (N.R.H., W.Y.K., M.M., H.E.B., L.T., E.F., J.F.L., E.H.C.), MR-Center (W.Y.K., S.A.T.), and Department of Pathology (S.H.), Aarhus University Hospital, Skejby, Denmark; Division of Image Processing, Leiden University Medical Center, Leiden, the Netherlands (S.T.); and Department of Thoracic Surgery, Aarhus University Hospital, Skejby, Aarhus, Denmark (P.H.N.). Search for more papers by this author , Jens Flensted LassenJens Flensted Lassen From the Department of Cardiology (N.R.H., W.Y.K., M.M., H.E.B., L.T., E.F., J.F.L., E.H.C.), MR-Center (W.Y.K., S.A.T.), and Department of Pathology (S.H.), Aarhus University Hospital, Skejby, Denmark; Division of Image Processing, Leiden University Medical Center, Leiden, the Netherlands (S.T.); and Department of Thoracic Surgery, Aarhus University Hospital, Skejby, Aarhus, Denmark (P.H.N.). Search for more papers by this author , Per Hostrup NielsenPer Hostrup Nielsen From the Department of Cardiology (N.R.H., W.Y.K., M.M., H.E.B., L.T., E.F., J.F.L., E.H.C.), MR-Center (W.Y.K., S.A.T.), and Department of Pathology (S.H.), Aarhus University Hospital, Skejby, Denmark; Division of Image Processing, Leiden University Medical Center, Leiden, the Netherlands (S.T.); and Department of Thoracic Surgery, Aarhus University Hospital, Skejby, Aarhus, Denmark (P.H.N.). Search for more papers by this author and Evald Høj ChristiansenEvald Høj Christiansen From the Department of Cardiology (N.R.H., W.Y.K., M.M., H.E.B., L.T., E.F., J.F.L., E.H.C.), MR-Center (W.Y.K., S.A.T.), and Department of Pathology (S.H.), Aarhus University Hospital, Skejby, Denmark; Division of Image Processing, Leiden University Medical Center, Leiden, the Netherlands (S.T.); and Department of Thoracic Surgery, Aarhus University Hospital, Skejby, Aarhus, Denmark (P.H.N.). Search for more papers by this author Originally published1 Mar 2013https://doi.org/10.1161/CIRCIMAGING.112.979997Circulation: Cardiovascular Imaging. 2013;6:352–354IntroductionDrug-eluting stents (DES) minimized the occurrence of in-stent restenosis but with a penalty of increased risk of late stent thrombosis.1 In patients with late stent thrombosis, adverse vessel wall reactions such as uncovered and malapposed stent struts, coronary aneurysms, and accelerated neoatherosclerosis2 have been identified. The stent polymer is suspected to induce an inflammatory response,3 resulting in vessel wall abnormalities.Identification of patients with an inflammatory response to DES might be essential in preventing late stent thrombosis. Inflammatory processes increase vessel wall permeability, leading to edema, and both native and peri-stent vessel wall inflammation may be associated with tissue edema. Cardiovascular magnetic resonance (CMR) performed with a T2-weighted short-τ inversion recovery sequence (T2-STIR) has recently been shown to identify localized coronary edema in the culprit artery of patients with acute myocardial infarction.4 Parameters for the ECG-triggered, navigator-gated, dark-blood, T2-STIR fast-spin-echo sequence were as follows: repetition time, 2 RR intervals; echo time, 100 milliseconds; echo train length, twenty 0.68×0.68×8-mm3 voxels; and 2 signal averages. Here we present 3 patients treated with DES (Cypher Select+, Cordis, Johnson & Johnson, Miami Lakes, FL) who demonstrate peri-stent edema as a possible marker of stent-induced coronary inflammation.Patient 1A 41-year-old woman experienced very late stent thrombosis 15 months after treatment with DES in the proximal left anterior descending artery (LAD). Coronary angiography showed peri-stent staining in the proximal LAD (Figure 1, left), suggestive of adverse vessel wall reaction. Frequency-domain optical coherence tomography (C7, St. Jude Medical, St. Paul, MN) showed coronary aneurysms in the stented area of the LAD with several thrombi (Figure 1C, middle; Movie I in the online-only Data Supplement). T2-STIR CMR demonstrated localized edema in the stented LAD area and in the native atherosclerotic coronary vessel wall at the proximal LAD and left main coronary artery, supporting an inflammatory cause (Figure 1A–1C, right). The patient was treated with dual antiplatelet therapy indefinitely. Follow-up was performed at 20 months to evaluate whether cessation of dual antiplatelet therapy before necessary, unrelated major surgery was safe. Progression of the vessel wall changes was detected (optical coherence tomography; Movie I in the online-only Data Supplement), and the patient was treated with bypass surgery. Histology of the peri-stent vessel wall verified infiltration by degranulating eosinophils (Figure 1G).Download figureDownload PowerPointFigure 1. Coronary angiogram from patient 1 with stent thrombosis after 15 months showing peri-stent staining in the proximal left anterior descending artery (LAD, top). Optical coherence tomography (OCT) (A–C) showed an eccentric fibrotic plaque formation (yellow arrows) in the left main coronary artery (A) and, in the proximal LAD circumflex artery bifurcation, a tangential dropout artifact (yellow star in B). The stented area of the LAD revealed several thrombi (dotted yellow arrows in C) and aneurysm formation (An). The stent struts are highlighted by the yellow arrowheads. T2-weighted short-τ inversion recovery (T2-STIR) cardiac magnetic resonance (CMR) immediately after the medically treated stent thrombosis demonstrated hyperintense signal intensity indicative of coronary edema (D–F, white arrows) corresponding to the atherosclerotic plaques in the vessel wall of the proximal LAD (E) extending to the left main coronary artery (D). The stented area also demonstrated the presence of peri-stent edema (F). Histology of excised peri-stent vessel (obtained at bypass surgery at 21 months) showed infiltration by eosinophils (G). DES indicates drug-eluting stents.Patient 2A 42-year-old man was treated by DES in the LAD and first diagonal artery. Baseline study optical coherence tomography showed well-apposed stent struts in the LAD (Figure 2C). At the planned 8-month follow-up, the coronary angiography showed extensive peri-stent staining (Figure 2A). Multiple aneurysms in a flower-like pattern were identified by optical coherence tomography (Figure 2D and 2E; Movie II in the online-only Data Supplement). Stent struts were apposed despite the severe vessel wall abnormalities. A high proportion of uncovered struts were identified. T2-STIR CMR at 8 months demonstrated peri-stent edema (Figure 2B).Download figureDownload PowerPointFigure 2. Coronary angiogram from patient 2 at the 8-month follow-up after treatment by drug-eluting stents (DES) showed substantial peri-stent staining in the proximal left anterior descending artery (LAD; A). T2-weighted short-τ inversion recovery (T2-STIR) cardiac magnetic resonance (CMR) showed hyperintense signal intensity (white arrow in B) in the peri-stent area of the proximal LAD, indicating the presence of peri-stent edema (B). Optical coherence tomography (OCT) after percutaneous coronary intervention showed well-apposed stent struts with some stent distortion caused by final kissing balloon dilatation (C). At the 8-month follow-up, OCT showed aneurysm formation between struts, resulting in a flower-like pattern with large extra stent space (D). The extent of sacculate evaginations following the strut pattern was readily visualized by 3-dimensional OCT reconstruction of the stented vessel (E) (QAngioOCT RE, Medis Specials, the Netherlands).Patient 3A 61-year-old woman was treated by 3 DES in the right coronary artery and in the LAD. Elective coronary angiography after 4 weeks revealed early peri-stent staining, indicative of aneurysm formation around the implanted stents. Planned coronary angiography after 1 year showed increased peri-stent staining (Figure 3, top). CMR at 1 year showed peri-stent tissue edema at the proximal LAD extending to the left main coronary artery, where an eccentric plaque was located (Figure 3A and 3B). The patient underwent subacute coronary bypass grafting. Histological examination of a biopsy from the stented area of the LAD showed substantial peri-strut inflammation with degranulating eosinophils.Download figureDownload PowerPointFigure 3. Severe, persistent aneurysm formation at planned angiographic evaluation after 12 months (top). Peri-stent edema in the drug-eluting stent (DES)–treated left anterior descending artery (LAD; B) extending to the left main coronary artery (A) demonstrated by T2-weighted short-τ inversion recovery (T2-STIR) cardiac magnetic resonance (CMR; white arrows, bottom).These 3 cases represent the first in vivo demonstration of peri-stent edema after treatment by DES by noninvasive, non–contrast-enhanced imaging. Coronary edema detected by T2-STIR CMR might emerge as a surrogate marker for inflammation, thus possibly identifying patients with an increased risk of late coronary stent thrombosis.DisclosuresDr Holm has received research grants and speaker fees from St. Jude Medical; research grant from Cordis; and travel grants, research grants, and speakers fees from Terumo. Dr Botker received speaker fees from Zealand Pharma. Dr Christiansen received research grants, travel grants, and speaker fees from St. Jude Medical, Terumo, and Cordis. Dr Tu has held a position at Medis Medical Imaging. Dr Lassen received research grants, travel grants, and speaker fees from St. Jude Medical, Terumo, and Cordis. Dr Thuesen received research grants, travel grants, and speaker fees from Terumo and Cordis. The other authors report no conflicts.FootnotesThe online-only Data Supplement is available at http://circimaging.ahajournals.org/lookup/suppl/doi:10.1161/CIRCIMAGING.112.979997/-/DC1.Correspondence to Niels Ramsing Holm, MD, Department of Cardiology, Aarhus University Hospital, Skejby, Brendstrupgaardsvej 100, DK-8200 Aarhus N, Denmark. E-mail [email protected]References1. Jensen LO, Maeng M, Kaltoft A, Thayssen P, Hansen HH, Bottcher M, Lassen JF, Krussel LR, Rasmussen K, Hansen KN, Pedersen L, Johnsen SP, Soerensen HT, Thuesen L. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions.J Am Coll Cardiol. 2007; 50:463–470.CrossrefMedlineGoogle Scholar2. Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, Kolodgie FD, Finn AV, Virmani R. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents.J Am Coll Cardiol. 2011; 57:1314–1322.CrossrefMedlineGoogle Scholar3. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, Togni M, Wenaweser P, Billinger M, Seiler C, Gay S, Meier B, Pichler WJ, Jüni P, Virmani R, Windecker S. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis.Circulation. 2009; 120:391–399.LinkGoogle Scholar4. Kim WY, Christiansen EH, Thrysøe SA, Al-Mashhadi RH, Bøtker HE, Bøttcher M, Holm NR, Falk E. First in vivo demonstration of coronary edema in culprit lesion of patient with acute coronary syndrome by cardiovascular magnetic resonance.Circ Cardiovasc Imaging. 2011; 4:344–346.LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Ingle R, Youssef A, Nishimura D and Yang P (2019) Cardiovascular Magnetic Resonance Angiography Cardiac CT, PET & MR, 10.1002/9781118754467.ch7, (236-281) Dweck M, Puntmann V, Vesey A, Fayad Z and Nagel E (2016) MR Imaging of Coronary Arteries and Plaques, JACC: Cardiovascular Imaging, 10.1016/j.jcmg.2015.12.003, 9:3, (306-316), Online publication date: 1-Mar-2016. Keegan J (2014) Coronary artery wall imaging, Journal of Magnetic Resonance Imaging, 10.1002/jmri.24766, 41:5, (1190-1202), Online publication date: 1-May-2015. Goldberg A, Zdorovyak A, Rosenfeld I and Nordkin I (2015) Early development of coronary artery aneurysms after implantation of biolimus-eluting stent with biodegradable polymer, International Journal of Cardiology, 10.1016/j.ijcard.2015.02.082, 184, (487-488), Online publication date: 1-Apr-2015. Bloch L, Hansen A, Pedersen S, Honge J, Kim W and Hansen E (2014) Imaging of carotid artery vessel wall edema using T2-weighted cardiovascular magnetic resonance, Journal of Cardiovascular Magnetic Resonance, 10.1186/1532-429X-16-22, 16:1, Online publication date: 1-Dec-2014. March 2013Vol 6, Issue 2 Advertisement Article InformationMetrics © 2013 American Heart Association, Inc.https://doi.org/10.1161/CIRCIMAGING.112.979997PMID: 23512782 Manuscript receivedAugust 19, 2012Manuscript acceptedDecember 13, 2012Originally publishedMarch 1, 2013 Keywordsmagnetic resonance imagingstent thrombosisoptical coherence tomographyPDF download Advertisement SubjectsChronic Ischemic Heart DiseaseComputerized Tomography (CT)ImagingMyocardial InfarctionStent
What problem does this paper attempt to address?
-
Clinical Outcomes and Risk Factors of Coronary Artery Aneurysms after Successful Percutaneous Coronary Intervention and Drug-Eluting Stent Implantation for Chronic Total Occlusions
Xin Zhong,Hua Li,Chenguang Li,Nobel Zong,David Liem,X'avia Chan,Shuning Zhang,Youen Zhang,Xinggang Wang,Xing Wu,Wenbin Zhang,Kang Yao,Xuebo Liu,Lei Ge,Kai Hu,Juying Qian,Mario Deng,Junbo Ge
DOI: https://doi.org/10.1016/j.ijchv.2014.06.004
2014-01-01
Abstract:ObjectiveThe study aimed to analyze the risk factors and long-term outcomes associated with coronary artery aneurysms (CAAs) after successful percutaneous coronary intervention (PCI) and drug-eluting stent (DES) implantation in patients with CTOs.BackgroundThere are sporadic data available on post-procedure CAAs after transcatheter revascularization for CTOs.Methods and resultsA total of 141 patients with 149 CTOs who underwent successful CTO-PCI and DES implantation with angiographic follow-up from 2004 to 2010 were included. Patients were divided into CAA group and non-CAA group according to the presence of CAAs in the follow-up angiography. The independent predictors and major adverse cardiac events (MACEs) including cardiac death, myocardial infarction (MI) and target-vessel revascularization (TVR) were compared between two groups. The incidence of CAAs was 11.4% (17/149) after index procedure. Multivariate analysis showed that age (OR: 0.925, CI 0.873–0.980, P = 0.008), ostial occlusion (OR: 6.715, CI 1.473–30.610, P = 0.014), the parallel wire technique (OR: 6.167, CI 1.709–22.259, P = 0.005) and DES length (OR: 1.030, CI 1.002–1.058, P = 0.036) were the independent predictors of CAAs after successful CTO-PCI and DES implantation. MACEs were similar between two groups (adjusted hazard ratio 0.670; 95% CI 0.160–2.808; P = 0.584) during the 5-year follow-up.ConclusionsThe independent predictors of CAAs after successful CTO-PCI and DES implantation are age, ostial occlusion, the parallel wire technique and DES length. CAAs after index procedure are not frequently associated with adverse clinical events under dual antiplatelet therapy. Further large clinical studies are warranted to explore the clinical implications of patients with this distinct new entity.
-
Drug-eluting stent, but not bare metal stent, accentuates the systematic inflammatory response in patients.
Junhui Liu,Xiao-Zhen Zhuo,Weimin Liu,Zhaofei Wan,Xinhong Wang,Weiping Zhang,Shanshan Gao,Zuyi Yuan,Yue Wu
DOI: https://doi.org/10.1159/000358508
IF: 1.9
2014-01-01
Cardiology
Abstract:Objective: The systematic pro-inflammatory responses after percutaneous coronary intervention with drug-eluting stents (DES) remain poorly defined. Therefore, we compared the systematic pro-inflammatory state of circulating mononuclear cells (MNCs) between DES and bare metal stent (BMS) implantation. Methods: Patients with indications for treatment with stents were randomized in a 1: 1 ratio to placement of DES or BMS. The primary endpoint was a change of pro-inflammatory state at 12 weeks postprocedure. Results: Thirty-six consecutive patients received DES or BMS. At 12 weeks after stent implantation, the lipid profile and high-sensitivity C-reactive protein (hs-CRP) improved significantly in both groups. The mRNA levels and plasma concentrations of interleukin-6, tumor necrosis factor-alpha and matrix metalloproteinase-9 were significantly elevated in the DES group, which was not observed in the BMS group. An increase in NF-kappa B binding activity and a decrease in PPAR-gamma expression in MNCs were observed in the DES group, along with increases in IkB phosphorylation and p50 expression. However, similar changes were not observed in the BMS group. Conclusions: Systematic inflammatory responses were accentuated after the patients were treated percutaneously with DES, despite their improved lipid profile and hs-CRP. These data may provide fundamental information for optimizing therapeutic strategy in the era of DES. (c) 2014 S. Karger AG, Basel
-
Long-Term Effects of Drug-Eluting Stents Versus Bare Metal Stents on Patients with Acute St-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes of 3-Year Clinical Follow-Up
Wang Chong-hui,Fang Quan,Zhang Shu-yang,Shen Zhu-jun,Fan Zhong-jie,Jin Xiao-feng,Zeng Yong,Liu Zhen-yu,Xie Hong-zhi,Yang Ming
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.2012.16.001
IF: 6.133
2012-01-01
Chinese Medical Journal
Abstract:Background The long-term safety and efficacy of drug-eluting stents (DES) versus bare metal stents (BMS) are unclear and controversial issues in patients with acute ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The purpose of this study was to compare the long-term outcome of STEMI patients undergoing primary PCI with DES versus BMS implantation.Methods A total of 191 patients with acute STEMI undergoing PCI from Jan. 2005 to Dec. 2007 were enrolled. Patients received DES (n=83) or BMS (n=108) implantation in the infarction related artery according to physician's discretion. The primary outcome was the occurrence of major adverse cardiac events (MACE), which was defined as a composite of death, myocardial infarction (MI), target vessel revascularization (TVR) and stent thrombosis. The difference of MACE was observed between DES and BMS groups.Results The clinical follow-up duration was 3 years ((41.7 +/- 16.1) months). MACE occurred in 20 patients during three years follow-up. Logistic regression analysis showed that the left ventricular ejection fraction (LVEF) was an independent predictor for MACE in the follow-up period (P=0.0301). There was no significant difference in all-cause mortality (3.61% vs. 7.41%, P=0.2647), the incidence of myocardial infarction (0 vs. 0.93%, P=0.379) and stent thrombosis (1.20% vs. 1.85%, P=0.727) between the DES group and BMS group. The incidence of MACE was significantly lower in the DES group compared to the BMS group (4.82% vs. 14.81%, P=0.0253). The rate of TVR was also lower in the DES group (0 vs. 5.56%, P=0.029). In the DES group, there was no significant difference in the incidence of MACE between sirolimus eluting stents (SES, n=73) and paclitaxel-eluting stents (PES, n=10) subgroups (2.74% vs. 20.00%, P>0.05).Conclusions This finding suggested that drug-eluting stents significantly reduced the need for revascularization in patients with acute STEMI, without increasing the incidence of death or myocardial infarction. Use of DES significantly decreased the incidence of MACE compared with BMS during the 3-year follow-up. Chin Med J 2012;125(16):2803-2806
-
An Intravascular Ultrasound Study of Cypher, Taxus, and Endeavor Stents on Relation Between Neointimal Proliferation and Residual Plaque Burden
C. H. Lee,J. Zhang,A. Kailasam,B. C. Tai,F. Ye,A. Low,S. G. Teo,S. Chen,H. C. Tan,Y. T. Lim
DOI: https://doi.org/10.1111/j.1540-8183.2008.00397.x
2008-01-01
Journal of Interventional Cardiology
Abstract:BACKGROUND:Studies on balloon angioplasty, atherectomy, and bare metal stent have shown a direct relation between residual plaque burden and restenosis. We investigated the relation between residual plaque burden and neointimal proliferation after drug-eluting stent (DES) implantation.METHODS:Over a period of 12 months, 65 patients (Cypher, n = 25; Taxus, n = 28; Endeavor, n = 12) from two centers underwent intravascular ultrasound (IVUS) examination at 8.2 (interquartile range 6.8-9.5) months after coronary stent implantation in native de novo coronary arteries. IVUS images were acquired with motorized pullback at 0.5 mm/s, and cross-sectional measurements were performed within the stents at 1-mm intervals. The following measurements were obtained: (1) lumen area (LA), (2) stent area (SA), (3) external elastic membrane area (EEMA), (4) percent neointimal hyperplasia area (SA-LA/SA) x 100, and (5) percent residual plaque area (EEMA-SA)/EEMA x 100.RESULTS:The analysis of 1,173 cross sections (Cypher, n = 436; Taxus, n = 532, Endeavor, n = 205) using mixed model to account for intrasubject correlation showed an absence of relation between percent residual plaque area and percent neointimal hyperplasia area (P = 0.189). Mean residual plaque burden outside the stent for Cypher, Taxus, and Endeavor groups was similar (45.7%, 44.8%, and 42.4%, respectively). Mean percent neointimal hyperplasia area for the Cypher, Taxus, and Endeavor groups was 12.0%, 15.0%, and 16.2%, respectively (P = 0.163).CONCLUSION:In patients after first-generation DES implantation and without significant in-stent restenosis, late in-stent neointimal proliferation is not related to the amount of residual plaque burden after stent implantation. This suggests against routine plaque removal before DES implantation to reduce neointimal proliferation.
-
Intravascular Imaging for Guiding In‐Stent Restenosis and Stent Thrombosis Therapy
Emrah Erdogan,Retesh Bajaj,Alexandra Lansky,Anthony Mathur,Andreas Baumbach,Christos V. Bourantas
DOI: https://doi.org/10.1161/JAHA.122.026492
2022-11-04
Abstract:Advances in stent technology and the design of endovascular devices with thinner struts, anti‐inflammatory and antithrombotic polymers, and better drug kinetics have enhanced the safety and efficacy of the second‐generation drug‐eluting stents and broadened their use in the therapy of high‐risk patients and complex anatomies. However, despite these developments, in‐stent restenosis and stent thrombosis remain the Achilles' heel of percutaneous coronary intervention, with their cumulative incidence reaching up to 10% at 5 years following percutaneous coronary intervention. The treatment of stent failure poses challenges and is associated with a worse prognosis than conventional percutaneous coronary intervention. Several studies have recently highlighted the value of intravascular imaging in identifying causes of stent failure, underscored its role in treatment planning, and registries have shown that its use may be associated with better clinical outcomes. The present review aims to summarize the evidence in the field; it discusses the value of intravascular imaging in identifying the mechanisms of in‐stent restenosis and stent thrombosis in assessing the morphological characteristics of neointima tissue that appears to determine long‐term outcomes in evaluating procedural results, and presents the findings of studies supporting its value in guiding therapy in stent failure. Nonstandard Abbreviations and Acronyms DCB drug‐coated balloon DES drug‐eluting stent ISR in‐stent restenosis IVBT intravascular brachytherapy POBA plain old balloon angioplasty ST stent thrombosis TLR target lesion revascularization WSS wall shear stress New developments in percutaneous coronary intervention (PCI) technology, including the design of efficient guidewires, adjunctive PCI devices, and advances in stent technology, have simplified the procedure, reduced the risk of complications, increased procedural success, and improved long‐term outcomes, especially in high‐risk patients and complex lesions. Nevertheless, in selected patients and in challenging anatomies, the event rate remains high. 1 In‐stent restenosis (ISR) constitutes the most common cause of stent failure in the United States and United Kingdom, 2 , 3 and its management is challenging because reintervention is needed in 10.3% to 36.8% of the patients at 3‐year follow‐up. 4 , 5 Although the incidence of stent thrombosis (ST) has been considerably reduced after the introduction of the second‐generation drug eluting stents (DES) as shown in clinical trials, in clinical practice, the ST rates are higher and are associated with devastating consequences, because in such cases the clinical presentation is often death or myocardial infarction. 6 , 7 , 8 Over the past years, several endovascular therapies have been introduced to successfully treat ISR that were evaluated in numerous randomized control studies (Figure S1, Table S1). Despite the undoubted value of these studies in clinical practice, they all had a significant limitation: they did not use intravascular imaging to identify the underlying mechanisms of stent failure and assess neointima characteristics that are likely to affect clinical outcomes. Intravascular imaging studies have underscored the importance of correcting causes of stent failure and the role of neointima composition on vessel wall response after repeat revascularization. Consequently, the routine use of intravascular imaging has IIa/C indication in the European Society of Cardiology guidelines for detecting causes of stent failure and personalizing therapy. 9 This review aimed to provide a comprehensive overview in the field, discusses the potential value of intravascular imaging in identifying causes of ISR and ST, presents clinical outcomes from small‐scale studies assessing different interventional strategies in challenging scenarios, and proposes a treatment algorithm that relies on the information derived from intravascular imaging to effectively treat ISR and ST. UNDERLYING MECHANISMS OF IN‐STENT RESTENOSIS The introduction of DES and developments in stent polymers and drug kinetics have si -Abstract Truncated-
-
Late Stent Malapposition and Marked Positive Vessel Remodeling after Sirolimus-Eluting Coronary Stent Implantation
F Zhang,JY Qian,JB Ge
DOI: https://doi.org/10.1097/00029330-200602020-00016
2006-01-01
Abstract:It has been reported that positive remodeling, regression of neointimal hyperplasia, and late malapposition are associated with brachytherapy, one of the approaches to prevent first-time and recurrent in-stent restenosis.1,2 Recently, some drug-eluting stents have been demonstrated to dramatically reduce restenosis rates.3,4 Despite these promising results, these drug-eluting stents may have the same potential risks as brachytherapy, with some similarities between the 2 technologies in anti- proliferative effects on vascular smooth muscle cells and endothelial cells. We reported a case of late stent malapposition and marked positive vessel remodeling after sirolimus-eluting coronary stent implantation. CASE REPORT The patient was a 32-year-old male admitted in the hospital on August 23, 2004 because of chest oppression after subacute anterior myocardial infarction. He had no cardiac risk factors except smoking. Coronary angiogram showed a total occlusion of the proximal left anterior descending artery (LAD), and a successful angioplasty was performed using a 3.0 mm×28 mm sirolimus-eluting Cypher SelectTM stent (Cordis, USA) with the pressure of 1419 kPa after predilatation (Fig. A). Intravascular ultrasound (IVUS) imaging showed complete apposition of the stent struts against the vessel wall over the entire length of the stent (Fig. B).Fig.: Angiographic (A) and IVUS (B) pictures of left anterior descending artery immediately after Cypher implantation. Angiographic (C) and IVUS (D) pictures at 9 months follow up. The white arrows indicate a “zig-zag” phenomenon (C) and lacunar spaces beyond the stent struts, in which blood flow is evident (D). Compared with the baseline IVUS, a significant increase in vessel CSA and plaque CSA is found at follow up, indicative of marked positive vessel remodeling. IVUS: Intravascular ultrasound, CSA: cross-sectional area.Nine months later, repeated coronary angiography by scheduled follow up was performed and a “zig-zag” phenomenon in the stented segment was found (Fig. C). Subsequent IVUS imaging found that there were several gaps between the struts of the stent and the vessel wall, indicating the late acquired stent malapposition. Quantitative measurement showed a significant enlargement in external elastic membrane (EEM) cross-sectional area (CSA, 14.1 mm2 at baseline, 29.9 mm2 at follow up) and in plaque and media CSA (from 7.6-20.5 mm2, Fig. D), indicating marked positive vessel remodeling. The maximum depth between stent struts and the vessel wall was 1.0 mm. There was no change in stent CSA, and the effective lumen increased because of the late malapposition. The increase in EEM area (25.8 mm2) was larger than that in plaque and media CSA (12.9 mm2). In stent segment, the EEM area of the stent segment was significantly larger than that of the average reference segment, with a remodeling index of 1.9, and the maximum vessel diameter was extraordinarily large with stent malapposition, reaching 6.5 mm. Because of the lack of information regarding malapposition as the cause of subacute occlusion in drug-eluting stent, the patient did not undergo any further interventional therapy and was suggested to take clopidogrel for long time and will be closely followed up with repeated angiography and IVUS to assess the potential progression of the malapposition. DISCUSSION Late stent malapposition, a separation of the stent struts from the intimal surface of the arterial wall that is not present immediately after implantation, has been previously documented after brachytherapy and bare-metal stent implantation.1,2,5 A subgroup analysis of the RAVEL trial reveals a late stent malapposition after SES implantation with an significantly higher incidence than bare-metal stent.3 But the mechanistic interpretation of these data are hampered by the fact that no IVUS analysis had been performed during the baseline procedure. Thus, it is unclear whether the stents are already incompletely apposed against the vessel wall during the index procedure or this is a late acquired effect. In the present case report, serial IVUS was performed and revealed late stent malapposition at follow up, with complete apposition of the stent struts against the vessel wall over the entire length of the stent at baseline. No significant change in stent, plaque behind stent, and vessel volume is described after SES implantation by Degertekin et al.6 However, significant vascular positive remodeling is demonstrated by ectatic areas of vessel and plaque behind stent compared with the index parameters in the present case with late stent malapposition. The findings suggest that late stent malapposition after SES implantation may be associated with an increase in EEM (positive remodeling) out of proportion to the increase in peri-stent tissue hyperplasia. In the situation of malapposition, there are some gaps between the stent struts and the vessel wall. These gaps could be filled by contrast media during angiography and appeared as the “zig-zag”phenomenon just in the stented segment. Whether the late stent malapposition will be the potential mechanism of late in-stent thrombosis remains further investigation and long-term follow up of the patient receiving drug-eluting stent.
-
The Double-Faced Metabolic and Inflammatory Effects of Standard Drug Therapy in Patients after Percutaneous Treatment with Drug-Eluting Stent
Yue Wu,Weiping Zhang,Weimin Liu,Xiaozhen Zhuo,Zhao,Zuyi Yuan
DOI: https://doi.org/10.1016/j.atherosclerosis.2010.12.007
IF: 5.3
2011-01-01
Atherosclerosis
Abstract:Objective: The inflammatory responses after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) remain poorly understood; therefore, this study aims to investigate the changes of metabolic parameters and systematic inflammatory status of circulating mononuclear cells (MNC) in patients after percutaneous treatment with DES implantation.Methods and results: Twenty-seven patients with acute coronary syndrome who would undergo PCI with DES implantation were consecutively recruited and treated with standard drug therapy from the start of hospitalization. Metabolic parameters including total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein improved significantly after 12 weeks of standard medication, whereas the plasma levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), macrophage migration inhibitory factor (MIF), and matrix metalloproteinase-9 (MMP-9) increased (P = 0.012, 0.035, 0.062 and 0.112, respectively, compared to the baseline). The NF-kappa B DNA binding activity in MNC increased significantly compared to the baseline (P = 0.015), whereas I kappa B-beta and PPAR-gamma were significantly suppressed (P = 0.046 and 0.002, respectively). There were strong correlations among the changes of metabolic parameters and the changes of proinflammatory factors; however, none of them is statistically significant.Conclusions: Standard drug therapy can improve the metabolic parameters but fail to restrain the proinflammatory state after PCI with DES implantation. Longer term endpoint-based studies are still needed for further exploration of the relationship between inflammatory factors and clinical cardiovascular events in the era of DES. Crown Copyright (C) 2010 Published by Elsevier Ireland Ltd. All rights reserved.
-
Neointima and neoatherosclerotic characteristics in bare metal and first- and second-generation drug-eluting stents in patients admitted with cardiovascular events attributed to stent failure: an optical coherence tomography study
Rodrigue Stettler,Jouke Dijkstra,Lorenz Räber,Ryo Torii,Yao-Jun Zhang,Antonios Karanasos,Shengnan Lui,Tom Crake,Steve Hamshere,Hector M Garcia-Garcia,Erhan Tenekecioglu,Muhiddin Ozkor,Stephan Windecker,Patrick W Serruys,Evelyn Regar,Anthony Mathur,Christos V Bourantas
DOI: https://doi.org/10.4244/EIJ-D-17-00051
2018-02-02
EuroIntervention
Abstract:Aims: The aim of this study was to assess neoatherosclerotic plaque morphology in bare metal (BMS) and first- and second-generation drug-eluting stents (DES) in patients presenting with an event attributed to stent failure. Methods and results: Thirty-five patients (11 implanted with BMS, 13 with a first-generation and 11 with a second-generation DES) admitted with an event due to stent failure who had neoatherosclerotic lesions on optical coherence tomography were included in the analysis. The lumen and stent borders were detected and the lipid and calcific tissue were identified in the neointima and their burden was estimated. The neointima attenuation and backscatter indices were computed and compared between the different stent types. Although there were no differences in the neointima burden, the BMS group exhibited thinner fibrous caps (p<0.001), and a numerically increased incidence of lipid-rich plaques (p=0.052) and macrophage accumulation (p=0.012). Neointima discontinuities (p=0.009) and thrombus (p=0.032) were seen more often in first-generation DES. In all stent types, neoatherosclerosis had focal manifestations. In neoatherosclerotic lesions the attenuation and backscatter indices were increased in BMS (p=0.031 and p=0.018, respectively) compared to DES; however, there were no differences between stents in the attenuation indices in subsegments located distally to neoatherosclerotic lesions which had low values in all stent types. Conclusions: Although there are differences in lipid burden and neointima characteristics in different stent types, in all stents neoatherosclerosis has focal manifestations indicating that, irrespective of the stent type, focal triggers are involved in the generation of vulnerable neolesions.
-
Association Between the Neutrophil-to-Lymphocyte Ratio and in-Stent Neoatherosclerosis and Plaque Vulnerability: An Optical Coherence Tomography Study
Ning Gu,Panke Chen,Xi Wang,Changyin Shen,Yi Deng,Jianling Chen,Yi Ma,Shuai Ma,Xingwei Hu,Ranzun Zhao,Bei Shi
DOI: https://doi.org/10.1097/fjc.0000000000001616
IF: 3.271
2024-11-08
Journal of Cardiovascular Pharmacology
Abstract:Percutaneous coronary intervention (PCI) has revolutionized the treatment of patients with coronary heart disease. 1 Compared with bare metal stents (BMS), drug-eluting stents (DES) substantially reduce angiographic and in-stent restenosis (ISR). 2,3 However, late and very late ISR still occur, which is attributed to in-stent neoatherosclerosis (ISNA), which proceeds more rapidly in DES compared with that of BMS. 4,5 Several studies have shown that local and systemic inflammatory responses play an important role in the development of ISNA and are predictors of ISR. 6,7 Therefore, a reliable and easy-to-measure biomarker of inflammation is needed to predict ISNA progression.
pharmacology & pharmacy,cardiac & cardiovascular systems
-
Vascular Response Occurring at 3 Months After Everolimus-Eluting Cobalt-Chromium Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction vs. Stable Coronary Artery Disease
Masaru Ishida,Daisuke Terashita,Tomonori Itoh,Hiromasa Otake,Yoshiro Tsukiyama,Tatsuo Kikuchi,Takatoshi Hayashi,Takahide Suzuki,Yoshiaki Ito,Takashi Morita,Kiyoshi Hibi,Takahiro Sawada,Takayuki Okamura,Junya Shite,Fumiaki Takahashi,Toshiro Shinke,Yoshihiro Morino
DOI: https://doi.org/10.1253/circj.CJ-20-0264
2020-10-23
Abstract:Background: Second-generation drug-eluting stents (DES) reduce the incidence of stent thrombosis, even in patients with ST-segment elevated myocardial infarction (STEMI). However, the early local vascular healing after DES implantation in STEMI lesions, which mainly concerns stent thrombosis, is still unclear.Methods and Results:We attempted to determine early local vascular healing 3 months after cobalt-chromium everolimus-eluting stent (CoCr-EES) implantation in STEMI lesions relative to stable coronary artery disease (CAD) lesions. This prospective, multicenter study analyzed 96 total lesions (STEMI=49, stable CAD=51) by frequency domain-optical coherence tomography (FD-OCT) performed post-procedure and at the 3-month follow-up. Although CoCr-EES implanted in STEMI were almost entirely covered at 3 months, they had a relatively high incidence of uncovered struts compared with stable CAD (5.5% vs. 1.6%, P<0.001). Intrastent thrombus in the 2 groups was primarily resolved at the 3-month follow-up (STEMI: 91.7%→26.5%, stable CAD: 74.5%→11.8%). Regarding irregular protrusion, complete resolution was observed in stable CAD (21.6%→0%), while a few stents remained in STEMI (79.2%→8.2%). Although there were almost no changes for the serial change of average lumen area in STEMI, there were slight but significant decreases in stable CAD [STEMI 0.08 (-0.44, 0.55) mm2, stable CAD -0.35 (-0.55, 0.11) mm2; P=0.009]. Conclusions: Although strut coverage after CoCr-EES implantation for STEMI lesions was slightly delayed, the healing process appeared to be acceptable in both STEMI and stable CAD.
-
THE DOUBLEFACED METABOLIC AND INFLAMMATORY EFFECTS OF STANDARD DRUG THERAPY IN PATIENTS AFTER DRUGELUTING STENT IMPLANTATION
Liu Weimin,Wang Lijun,Wu Yue,Liu Xiaojun,Yuan Zuyi
DOI: https://doi.org/10.1136/hrt.2010.208967.435
IF: 5.7
2010-01-01
Heart
Abstract:Objective The inflammatory response and the long-term endothelium healing after drug-eluting stent (DES) placement has recently emerged as a major concern. We investigated the change of metabolic parameters and systematic inflammatory status of circulating mononuclear cells (MNC) in patients after coronary DES implantation. Methods 27 patients with non-ST segmental elevation acute coronary syndrome that had undergone DES implantations were consecutively recruited and administrated with standard drug therapy for 12 weeks. The systematic inflammation on MNC was measured before DES implantations and after 12 weeks’ medication. NF-κB binding activity in MNC and expression of its subunits p65 and p50, and depressed cytosolic IκB expression of MNC were detected to reveal the systematic inflammation after DES implantations. Results Metabolic parameters total cholesterol, triglycerides, HDL, LDL improved significantly after 12 weeks’ standard medication, but plasma concentrations of interleukin-6, tumour necrosis factor-α, migration inhibitor factor, and matrix metalloproteinase-9 increased compared with baseline (p=0.012, 0.035, 0.062 and 0.112, respectively). The NF-kB DNA binding activity in MNC increased significantly compared with baseline (p=0.015), concomitantly with decreased IκB-β (p=0.052) and PPAR-γ in MNC (p=0.002). Although there were strong correlations within the change of metabolic parameters and within the change of proinflammatory factors, no significant correlations between them were observed. Conclusions Standard drug therapy can improve metabolic parameters, but fail to restrain the deteriorated systemic inflammatory responses prolonged at least 3 month. These findings raise concern about the efficiency of the current standard therapy in the era of DES. However, longer term endpoint-based studies are necessary to further explore the relationship between the inflammatory factors and the clinical cardiovascular events.
-
Clinical, electrocardiographic, echocardiographic, and angiographic predictors for the final infarct size assessed by cardiac magnetic resonance in acute STEMI patients after primary percutaneous coronary intervention
Ahmad Samir,Sherif Nagy,Magdy Abdelhamid,Hossam Kandil
DOI: https://doi.org/10.1186/s43044-024-00526-x
2024-08-24
Abstract:Background: Final infarct size (IS) after ST segment elevation myocardial infarction (STEMI) is a major predictor of mortality. Seeking early predictors for final IS can guide individualized therapeutic strategies for those recognized to be at higher risk. Results: Eighty STEMI patients successfully treated with primary percutaneous coronary intervention (pPCI) underwent baseline (within 48 h) 2D, 3D echocardiography with speckle tracking and then underwent cardiac magnetic resonance (CMR) at 3 months to assess the final IS. After recruitment, 4 patients were excluded for uncontainable claustrophobia while 76 patients completed the final analysis. The mean ± standard deviation age was 54.1 ± 10.9 years, 84% were males, 25% had diabetes, 26% were hypertensives, 71% were current smokers, 82% had dyslipidemia, and 18% had a family history of premature coronary artery disease. By 3 months, CMR was performed to accurately evaluate the final IS. In univariate regression analysis, the admission heart rate, baseline and post-pPCI ST elevation, STEMI location (anterior vs. inferior), highest peri-procedural troponin, large thrombus burden, baseline thrombolysis in myocardial infarction flow grade, the final myocardial blush grade, the 2D and 3D left ventricular ejection fraction (LVEF), and the 2D and 3D global longitudinal strain (GLS) parameters were significant predictors for the final IS. In the multivariate regression analysis, four models were constructed and recognized the residual post-PCI ST segment elevation, the highest peri-procedural troponin, the 2D-LVEF, 3D-LVEF, and 2D-GLS as significant independent predictors for final IS. Conclusions: In STEMI patients who underwent successful pPCI, early predictors for the final IS are vital to guide therapeutic decisions. The residual post-pPCI ST elevation, the highest peri-procedural troponin, and the baseline 2D-LVEF, 3D-LVEF, and 2D-GLS can be excellent and timely tools to predict the final IS.
-
Drug-eluting Stent: Where is the Way Out?
Yaling Han
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20130440
2013-01-01
Abstract:Since the first Palmaz-Schatz bare-metal stent (BMS) was implanted in human body in 1985, coronary stenting successfully resolved problem of the high restenosis rate in balloon dilatation era and soon became the primary means of clinical treatment of coronary artery disease. In order to meet the requirement of further reduction of the restenosis rate, drug-eluting stent (DES) was developed more than a decade later. With the excellent clinical efficacy, DESs established a milestone in the field of percutaneous coronary intervention (PCI). However, since the “stent thrombosis (ST) storm” triggered in 2006, the late ST after DES implantation quickly became a challenging problem.1,2 To solve this problem, a lot of advances have been achieved. Among them, biodegradable polymers and abluminal coating are two new technologies with bright future. DES WITH BIODEGRADABLE POLYMERS The causes of ST after implanting the first-generation DES are clearly multifactorial, and a portion of the blame has been attributed to the permanent polymer.3 Although the second-generation DES have already demonstrated impressive safety results at long-term follow-up,4,5 additional improvements are anticipated from the newer permanent polymer DES that have been developed. However, concerns persist over the presence of a nonerodable polymer, which remains exposed to the coronary artery environment long after its useful function has been served. Evidence from animal and human studies have suggested that these nonerodable polymers can cause persistent arterial wall inflammation and delayed vascular healing, both of which may subsequently have a role in precipitating ST and delayed restenosis.6-8 The findings from these studies accelerated the development of DES coated with biodegradable polymers. These stents offer the attractive combination of controlled drug elution in parallel with biodegradation of the polymer into inert monomers. Therefore, after biodegradation is complete, only a BMS remains, thereby reducing the long-term risks associated with the presence of a permanent polymer.9 In the issue of Chinese Medical Journal, a study from Kan et al10 demonstrates: (1) DES with either biodegradable or permanent polymer had lower value of late lumen loss (LLL); (2) LLL was less severe in the distal segment in relative to in-stent and proximal segment. In this non-randomized study, 300 consecutive patients having only biodegradable polymers or permanent polymer sirolimus eluting stent (SES) for all diseased vessels were enrolled (150 in EXCEL® biodegradable polymer group and 150 in FIREBIRD® permanent polymer group). The authors did not find the significant difference in LLL between the two groups. The study is timely necessary to elucidate the superiority of one domestic DES over another. And those results provided us a strong evidence to guide our clinical practice in the future. A randomized study is probably needed to identify the clinical benefit of one DES over the others other than angiographic parameters. In the issue of Chinese Medical Journal, Zhang et al11 conclude that: (1) Women had a lower major adverse cardiac events (MACE) and cardiac death rate than men after biodegradable polymer-coated SES (EXCEL®) in long term follow-up; (2) Effects of prolonged (over 6 months) dual antiplatelet therapy (DAPT) in preventing ST were similar with 6-month DAPT after EXCEL® stent implantation in both men and women groups, which has significant implication in patients who can not endure long term DAPT. Whether or not women gender is an independent predictor for worse outcome after PCI is still a subject of debate. Some studies confirm this phenomenon,12 whereas others have shown that the poorer outcomes in women are due to the presence of more clinical risk factors and comorbidities.13 More recent data suggest that long-term major clinical events14 and post-PCI mortality were not significantly different between men and women.15 In fact, in the BARI trial women was even a stronger predictor of better outcome than men after successful revascularization.16 So far, no prospective study has specifically focused on the evaluation of new generation DESs in women. The finding that EXCEL® stents for the treatment of women was superior is particularly encouraging. In present study, although women had higher proportions of clinical risk factors in comparison with men, the clinical results of cardiac death and MACE after index PCI procedures showed a low risk in women. The latter results suggested that a 6-month DAPT strategy after EXCEL® stent implantation might be safe for both men and women, which was consistent with the outcomes drawn from general patient cohorts.11,17-19 However, this conclusion needs further confirmation by head to head randomized trials. DES WITH ABLUMINAL COATING Abluminal coating can maximize the drug released into the vessel wall and minimize the systemic effect. Such a technique may facilitate a better stent endothelialization with positive impact on stent safety, minimizing long-term inflammation and decreasing ST rate, while maintaining anti-restenosis effect. Excel® stent is the first domestic device using abluminal coating design.19 Recently, its satisfactory and sustained five-year clinical safety and efficacy has been reported,17 evidenced by the low rates of MACE and ST when patients were treated with six months DAPT. Another domestic DES using abluminal design is FIREHAWK® stent. In addition to abluminal coating, its groove design allows the reduced drug content compared to previous generation DES. In this issue of Chinese Medical Journal, Xu et al20 showed: (1) The treatment of long coronary lesions with FIREHAWK® stent produces the similar results as observed in the FIREHAWK® FIM clinical trial;21 (2) The authors are optimistic of the treatment prospect of the FIREHAWK® for long coronary lesions. Those results are consistent with previous studies that LLL of FIREHAWK® is at the lower level compared with most other researches on DESs designed for treatment of long coronary artery diseases.22-24 One year results of FIREHAWK® TARGET I randomized controlled trial were released at TCT 2012, and its safety and efficacy have been approved. We are expecting long term (3-5 years) follow-up results from the serial studies. The articles previously introduced highlight the wealth of new DES technology and it is clear that no single DES design and polymer type will be suitable for all patients and lesion types. Therefore, a more individualized choice of DES, taking into account patient characteristics such as the ability to take long-term DAPT, and lesion characteristics such as presence or not of a bifurcation lesion will be important factors influencing DES selection. Encouragingly, the new DES technology appears to allow interventional cardiologists to make these choices, and there is great anticipation that the new DES technology will result in improved long-term clinical efficacy and safety.
-
Acute Response of the Noninfarcted Myocardium and Surrounding Tissue Assessed by T2 Mapping After STEMI
Luca Bergamaschi,Antonio Landi,Niccolò Maurizi,Carmine Pizzi,Laura Anna Leo,Dimitri Arangalage,Juan F. Iglesias,Eric Eeckhout,Juerg Schwitter,Marco Valgimigli,Anna Giulia Pavon
DOI: https://doi.org/10.1016/j.jcmg.2023.11.014
IF: 16.051
2024-01-26
JACC Cardiovascular Imaging
Abstract:Background ST-segment elevation myocardial infarction (STEMI) is associated with a systemic and local inflammatory response with edema. However, their role at the tissue level is poorly characterized. Objectives This study aims to characterize T2 values of the noninfarcted myocardium (NIM) and surrounding tissue and to investigate prognostic relevance of higher NIM T2 values after STEMI. Methods A total of 171 consecutive patients with STEMI without prior cardiovascular events who underwent cardiac magnetic resonance after primary percutaneous coronary intervention were analyzed in terms of standard infarct characteristics. Edema of the NIM, liver, spleen, and pectoralis muscle was assessed based on T2 mapping. Follow-up was available for 130 patients. The primary endpoint was major adverse cardiac events (MACE), defined as cardiovascular death, myocardial infarction, unplanned coronary revascularization or rehospitalization for heart failure. The median time from primary percutaneous coronary intervention to cardiac magnetic resonance was 3 days (IQR: 2-5 days). Results Higher (above the median value of 45 ms) T2 values in the NIM area were associated with larger infarct size, microvascular obstruction, and left ventricular dysfunction and did not correlate with C-reactive protein, white blood cells, or T2 values of the pectoralis muscle, liver, and spleen. At a median follow-up of 17 months, patients with higher (>45 ms) NIM T2 values had increased risk of MACE ( P < 0.001) compared with subjects with NIM T2 values ≤45 ms, mainly caused by a higher rate of myocardial reinfarction (26.3% vs 1.4%; P < 0.001). At multivariable analysis, higher NIM T2 values independently predicted MACE (HR: 2.824 [95% CI: 1.254-6.361]; P = 0.012). Conclusions Higher NIM T2 values after STEMI are independently associated with worse cardiovascular outcomes, mainly because of higher risk of myocardial infarction.
radiology, nuclear medicine & medical imaging,cardiac & cardiovascular systems
-
Diffuse Epicardial Involvement on Cardiac Magnetic Resonance Imaging.
Meng Jiang,Jianrong Xu,Ben He
DOI: https://doi.org/10.1001/jamacardio.2016.2557
2016-01-01
JAMA Cardiology
Abstract:A woman in her 50s was referred for evaluation of progressive shortness of breath over several months. No history of clinically significant fever was noted. The electrocardiogram showed ST-segment elevation in leads I, aVL, II, III, aVF, and V3-6 (Figure 1A), which was accompanied by fluctuating elevation of troponin-T levels (1.2-12.0 ng/mL). Angiography showed no evidence of coronary artery disease. Transthoracic echocardiography demonstrated restricted diastolic filling with a low left ventricular ejection fraction (40%). Treatment for heart failure was initiated. Cardiac magnetic resonance (CMR) imaging was then scheduled. Late delayed enhancement images showed a striking sawtooth pattern of hyperenhancement in the left ventricular epicardium (Figure 1B) and right-sided enhancement of the anteroseptum. Extensive myocardial edema was noted in the left ventricle via T2-weighted short tau inversion recovery imaging (Figure 1C). Chest and abdominal computed tomography (CT) showed no inflammatory changes or lymphadenopathy. Serum angiotensin-converting enzyme (ACE) levels were not elevated. The brain natriuretic peptide level was elevated (1550 pg/mL). Electrocardiogram A
-
Peri-therapeutic multi-modal hemodynamic assessment and detection of predictors for symptomatic in-stent restenosis after percutaneous transluminal angioplasty and stenting
Xiaowen Song,Hancheng Qiu,Shuo Yang,Yuqi Liu,Yong Cao,Shuo Wang,Jizong Zhao
DOI: https://doi.org/10.3389/fneur.2023.1136847
2023-04-18
Abstract:Backgrounds: This study performed multi-modal hemodynamic analysis including quantitative color-coded digital subtraction angiography (QDSA) and computational fluid dynamics (CFD) to delineate peri-therapeutic hemodynamic changes and explore the risk factors for in-stent restenosis (ISR) and symptomatic ISR (sISR). Methods: Forty patients were retrospectively reviewed. Time to peak (TTP), full width at half maximum (FWHM), cerebral circulation time (CCT), angiographic mean transit time (aMTT), arterial stenosis index (ASI), wash-in gradient (WI), wash-out gradient (WO) and stasis index were calculated with QDSA and translesional pressure ratio (PR) and wall shear stress ratio (WSSR) were quantified from CFD analysis. These hemodynamic parameters were compared between before and after stent deployment and multivariate logistic regression model was established to detect predictors for ISR and sISR at follow-up. Results: It was found that stenting generally reduced TTP, stasis index, CCT, aMTT and translesional WSSR while significantly increased translesional PR. ASI decreased after stenting, and during the mean follow-up time of 6.48 ± 2.86 months, lower ASI (<0.636) as well as larger stasis index were corroborated to be independently associated with sISR. aMTT showed a linear correlation with CCT before and after stenting. Conclusion: PTAS not only improved cerebral circulation and blood flow perfusion but also changed local hemodynamics significantly. ASI and stasis index derived from QDSA were proved to play a prominent role in risk stratification for sISR. Multi-modal hemodynamic analysis could facilitate intraoperative real-time hemodynamic monitoring and help the determination of the end point of intervention.
-
Myocardial injury in patients with acute ischemic stroke detected by cardiovascular magnetic resonance imaging
E Blaszczyk,S Hellwig,H Saad,R Ganeshan,H Stengl,C H Nolte,J B Fiebach,M Endres,J Kuhnt,J Gröschel,J Schulz-Menger,J F Scheitz
DOI: https://doi.org/10.1016/j.ejrad.2023.110908
Abstract:Background: Patients with acute ischemic stroke (AIS) are at high risk of adverse cardiovascular events. Until now, the burden of myocardial injury derived from cardiovascular magnetic resonance imaging (CMR) has not been established in this population. Methods: Patients with AIS underwent CMR at 3 Tesla within 120 h after the index stroke as part of a prospective, single-center study. Patients with persistent atrial fibrillation were excluded. Morphology and function of both cardiac chambers and atria were assessed applying SSFP cine. Myocardial tissue differentiation was based on native and contrast-enhanced imaging including late gadolinium enhancement (LGE) after 0.15 mmol/kg gadobutrol for focal fibrosis and parametric T2- and T1-mapping for diffuse findings. To detect myocardial deformation global longitudinal (GLS), circumferential (GCS) and radial (GRS) strain was measured applying feature tracking. Cardiac troponin was measured using a high-sensitivity assay (99th percentile upper reference limit 14 ng/L). T2 mapping values were compared with 20 healthy volunteers. Results: CMR with contrast media was successfully performed in 92 of 115 patients (mean age 74 years, 40% female, known myocardial infarction 6%). Focal myocardial fibrosis (LGE) was detected in 31 of 92 patients (34%) of whom 23/31 (74%) showed an ischemic pattern. Patients with LGE were more likely to have diabetes, prior myocardial infarction, prior ischemic stroke, and to have elevated troponin levels compared to those without. Presence of LGE was accompanied by diffuse fibrosis (increased T1 native values) even in remote cardiac areas as well as reduced global radial, circumferential and longitudinal strain values. In 14/31 (45%) of all patients with LGE increased T2-mapping values were detectable. Conclusions: More than one-third of patients with AIS have evidence of focal myocardial fibrosis on CMR. Nearly half of these changes may have acute or subacute onset. These findings are accompanied by diffuse myocardial changes and reduced myocardial deformation. Further studies, ideally with serial CMR measurements during follow-up, are required to establish the impact of these findings on long-term prognosis after AIS.
-
Association of Circulating PCSK9 With Ischemia-Reperfusion Injury in Acute ST-Elevation Myocardial Infarction
Christina TillerMagdalena HolzknechtIvan LechnerFritz OberhollenzerSebastian von der EmdeThomas KremserCan Gollmann-TepeköylüAgnes MayrAxel BauerBernhard MetzlerSebastian J. ReinstadlerMartin ReindlUniversity Clinic of Internal Medicine III,Cardiology and Angiology (C.T.,M.H.,I.L.,F.O.,S.E.,T.K.,A.B.,B.M.,S.J.R.,M.R.),Medical University of Innsbruck,Austria.University Clinic of Cardiac Surgery (C.G.-T.),Medical University of Innsbruck,Austria.University Clinic of Radiology (A.M.),Medical University of Innsbruck,Austria.
DOI: https://doi.org/10.1161/circimaging.123.016482
2024-08-22
Circulation Cardiovascular Imaging
Abstract:Circulation: Cardiovascular Imaging, Volume 17, Issue 8, Page e016482, August 1, 2024. BACKGROUND:Beyond therapeutic implications, PCSK9 (proprotein convertase subtilisin/kexin 9) has emerged as a promising cardiovascular biomarker. The exact role of PCSK9 in the setting of acute ST-elevation myocardial infarction (STEMI) is incompletely understood. We aimed to investigate the association of PCSK9 with ischemia-reperfusion injury, visualized by cardiac magnetic resonance imaging, in patients with STEMI revascularized by primary percutaneous coronary intervention (PCI).METHODS:In this prespecified substudy from the prospective MARINA-STEMI (NCT04113356) registry, we included 205 patients with STEMI. PCSK9 concentrations were measured from venous blood samples by an immunoassay 24 and 48 hours after PCI. The primary end point was defined as presence of intramyocardial hemorrhage according to cardiac magnetic resonance T2* mapping. Secondary imaging end points were the presence of microvascular obstruction (MVO) and infarct size. The clinical end point was the occurrence of major adverse cardiac events.RESULTS:We observed a significant increase in PCSK9 levels from 24 to 48 hours (268–304 ng/mL;P 0.05). PCSK9 concentrations 48 hours post-STEMI were higher in patients with intramyocardial hemorrhage (333 versus 287 ng/mL;P=0.004), MVO (320 versus 292 ng/mL;P=0.020), and large infarct size (323 versus 296 ng/mL;P=0.013). Furthermore, patients with increased PCSK9 levels >361 ng/mL at 48 hours were more likely to experience major adverse cardiac events (15% versus 8%;P=0.002) during a median follow-up of 12 months.CONCLUSIONS:In patients with STEMI, a significant increase in PCSK9 was observed from 24 to 48 hours after PCI. While PCSK9 levels after 24 hours were not related to myocardial or microvascular injury, PCSK9 after 48 hours was significantly associated with intramyocardial hemorrhage, MVO, and infarct size as well as worse subsequent clinical outcomes.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier; NCT04113356.
radiology, nuclear medicine & medical imaging,cardiac & cardiovascular systems
-
Prognostic impact of contrast-enhanced CMR early after acute ST segment elevation myocardial infarction (STEMI) in a regional STEMI network: results of the "Herzinfarktverbund Essen"
Oliver Bruder,Frank Breuckmann,Christoph Jensen,Markus Jochims,Christoph K Naber,Jörg Barkhausen,Raimund Erbel,Georg V Sabin,Herzinfarktverbund Essen
DOI: https://doi.org/10.1007/s00059-008-3102-8
Herz
Abstract:Background and purpose: In acute ST segment elevation myocardial infarction (STEMI), rapid restoration of epicardial coronary blood flow and myocardial perfusion limits infarct size and improves survival. Primary percutaneous coronary intervention (PCI) is superior to systemic fibrinolysis when instantly performed by experienced operators. The "Herzinfarktverbund Essen" (HIVE) is an urban STEMI network supporting direct patient transfer for primary PCI to four PCI centers covering a city area of 600,000 inhabitants. Integrated health care is an optional part of the HIVE allowing for reimbursement of medical innovations such as the evaluation of infarct size and the presence and extent of microvascular obstruction by contrast-enhanced cardiac magnetic resonance (CMR). The aim of this study was to assess the prognostic impact of contrast-enhanced CMR in the patient cohort of a regional STEMI network. Patients and methods: Within the 1st year (09/2004 to 08/2005) of the HIVE registry, 489 patients with acute myocardial infarction were treated in the four primary PCI centers. In one of the centers, including 143 patients, early CMR imaging using a standardized MR protocol for infarct quantification was performed whenever possible. Patients with hemodynamic instability, emergency coronary artery bypass grafting, resuscitation or death prior to CMR, claustrophobia, and other general contraindications to MRI had to be excluded, leaving 67 patients (54 male; mean age 61 +/- 12 years) for final evaluation. CMR was performed 4.5 +/- 2.5 days after admission on a 1.5-T MR scanner (Sonata, Siemens Medical Solutions, Erlangen, Germany) including steady-state free precession (SSFP) cine imaging for left ventricular function and single-shot inversion-recovery SSFP imaging for delayed enhancement (DE) and no-reflow (NR) evaluation following injection of 0.2 mmol/kg body weight gadodiamide (Omniscan, GE Healthcare Buchler, Munich, Germany). NR and DE volumes were calculated from single-shot short-axis stacks taken within the 1st minute following gadodiamide infusion by manual planimetry and summation of disks. 1-year follow-up data (telephone interview) for major adverse cardiac events (MACE: cardiac death, myocardial infarction, and rehospitalization for congestive heart failure, angina pectoris, or revascularization) were available for all patients. Results: DE as a measure of infarct size was 9% +/- 7% (range 0-33%) of left ventricular mass (LVM), and mean volume of microvascular obstruction was 2% +/- 3% (range 0-17%). Microvascular obstruction was present in 61% of patients. 16 MACE (one cardiac death, one myocardial infarction, and 14 rehospitalizations for congestive heart failure or unstable angina pectoris with PCI in six cases) occurred within the follow-up period of 430 +/- 63 days. Patients with MACE had larger infarcts (14% +/- 10% vs. 8% +/- 6% DE), lower left ventricular ejection fraction (LVEF 44% +/- 17% vs. 48% +/- 14%) and larger NR (3% +/- 5% vs. 2% +/- 3%). Using a stepwise logistic regression model, only NR > 0.5% of LVM was independently related to outcome (odds ratio = 3.9, confidence interval 1.1-13.9). Conclusion: NR as a correlate of microvascular obstruction remains independently related to prognosis in patients with acute myocardial infarction treated by PCI.
-
Acute Response in the Noninfarcted Myocardium Predicts Long-Term Major Adverse Cardiac Events After STEMI
Mayooran Shanmuganathan,Ambra Masi,Matthew K. Burrage,Rafail A. Kotronias,Alessandra Borlotti,Roberto Scarsini,Abhirup Banerjee,Dimitrios Terentes-Printzios,Qiang Zhang,Evan Hann,Elizabeth Tunnicliffe,Andrew Lucking,Jeremy Langrish,Rajesh Kharbanda,Giovanni Luigi De Maria,Adrian P. Banning,Robin P. Choudhury,Keith M. Channon,Stefan K. Piechnik,Vanessa M. Ferreira
DOI: https://doi.org/10.1016/j.jcmg.2022.09.015
2022-12-16
Abstract:Background Acute ST-segment elevation myocardial infarction (STEMI) has effects on the myocardium beyond the immediate infarcted territory. However, pathophysiologic changes in the noninfarcted myocardium and their prognostic implications remain unclear. Objectives The purpose of this study was to evaluate the long-term prognostic value of acute changes in both infarcted and noninfarcted myocardium post-STEMI. Methods Patients with acute STEMI undergoing primary percutaneous coronary intervention underwent evaluation with blood biomarkers and cardiac magnetic resonance (CMR) at 2 days and 6 months, with long-term follow-up for major adverse cardiac events (MACE). A comprehensive CMR protocol included cine, T2-weighted, T2∗, T1-mapping, and late gadolinium enhancement (LGE) imaging. Areas without LGE were defined as noninfarcted myocardium. MACE was a composite of cardiac death, sustained ventricular arrhythmia, and new-onset heart failure. Results Twenty-two of 219 patients (10%) experienced an MACE at a median of 4 years (IQR: 2.5-6.0 years); 152 patients returned for the 6-month visit. High T1 (>1250 ms) in the noninfarcted myocardium was associated with lower left ventricular ejection fraction (LVEF) (51% ± 8% vs 55% ± 9%; P = 0.002) and higher NT-pro-BNP levels (290 pg/L [IQR: 103-523 pg/L] vs 170 pg/L [IQR: 61-312 pg/L]; P = 0.008) at 6 months and a 2.5-fold (IQR: 1.03-6.20) increased risk of MACE (2.53 [IQR: 1.03-6.22]), compared with patients with normal T1 in the noninfarcted myocardium ( P = 0.042). A lower T1 (<1,300 ms) in the infarcted myocardium was associated with increased MACE (3.11 [IQR: 1.19-8.13]; P = 0.020). Both noninfarct and infarct T1 were independent predictors of MACE (both P = 0.001) and significantly improved risk prediction beyond LVEF, infarct size, and microvascular obstruction (C-statistic: 0.67 ± 0.07 vs 0.76 ± 0.06, net-reclassification index: 40% [IQR: 12%-64%]; P = 0.007). Conclusions The acute responses post-STEMI in both infarcted and noninfarcted myocardium are independent incremental predictors of long-term MACE. These insights may provide new opportunities for treatment and risk stratification in STEMI.
radiology, nuclear medicine & medical imaging,cardiac & cardiovascular systems